TL;DR
LL-37 vs VIP (Vasoactive Intestinal Peptide) highlights key contrasts in laboratory peptide research. LL-37 functions primarily as an antimicrobial agent while VIP acts as a neuropeptide modulator. Both appear in studies examining immune responses and inflammation but differ in origin, structure, and observed mechanisms.
LL-37 vs VIP (Vasoactive Intestinal Peptide) in Research Laboratory investigations frequently examine LL-37 and VIP (Vasoactive Intestinal Peptide) side by side due to overlapping interests in cellular signaling. Researchers source these compounds for in vitro and animal model experiments focused on peptide-receptor interactions.
Structural and Biochemical Differences LL-37 derives from the cathelicidin family and adopts an alpha-helical conformation in solution. In contrast, VIP (Vasoactive Intestinal Peptide) consists of 28 amino acids and belongs to the secretin-glucagon superfamily. These structural distinctions influence binding affinities observed in cell-based assays.
Functional Similarities in Laboratory Settings Both peptides demonstrate immunomodulatory properties during controlled experiments. Studies report LL-37 influencing cytokine profiles while VIP (Vasoactive Intestinal Peptide) appears in research exploring smooth muscle relaxation pathways. Shared observations include effects on inflammatory markers under specific culture conditions.
Applications in Peptide Comparison Studies Researchers utilize LL-37 and VIP (Vasoactive Intestinal Peptide) in parallel protocols to evaluate antimicrobial versus vasoactive responses. Common models include epithelial cell lines for LL-37 and neuronal tissue preparations for VIP. Such comparisons help delineate selective versus broad-spectrum activities in vitro.
Research Considerations for LL-37 and VIP When designing experiments, investigators note differences in stability and solubility profiles between LL-37 and VIP (Vasoactive Intestinal Peptide). LL-37 often requires specific buffers to maintain helical structure, whereas VIP demands attention to proteolytic degradation during extended assays. These factors guide protocol optimization in research environments.
Frequently Asked Questions
What are the primary research differences between LL-37 and VIP?
LL-37 is studied for antimicrobial activity in lab models, while VIP (Vasoactive Intestinal Peptide) is examined for neuropeptide and immunomodulatory effects in controlled experiments.
How do LL-37 and VIP compare in immune research?
Both peptides appear in studies of inflammation modulation, yet LL-37 focuses on pathogen defense mechanisms and VIP on regulatory signaling pathways.
Are LL-37 and VIP used together in studies?
Some laboratory protocols compare LL-37 and VIP (Vasoactive Intestinal Peptide) to contrast antimicrobial versus vasoactive responses in cell and tissue models.
What structural features distinguish LL-37 from VIP?
LL-37 forms alpha-helices from cathelicidin precursors; VIP (Vasoactive Intestinal Peptide) is a 28-amino-acid member of the secretin family with distinct receptor interactions.
Explore Further
Browse our [research peptide catalog](/shop) and review third-party [lab reports & COAs](/lab-reports) for every batch.
---
**Research use only.** The information above is provided for educational and laboratory research purposes only. The compounds discussed are not approved for human or veterinary use, diagnosis, treatment, or the prevention of any disease. Nothing here is medical advice.